Micro-X Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Micro-X kazanç ve gelirinin sırasıyla yıllık 68.7% ve 38.2% oranında artması tahmin edilirken, EPS'nin yıllık 87.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

68.7%

Kazanç büyüme oranı

87.8%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	16.1%
Gelir büyüme oranı	38.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

CHIA:MX1 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	52	4	N/A	2	1
6/30/2026	37	-5	N/A	-6	1
6/30/2025	25	-7	N/A	0	1
6/30/2024	15	-10	-7	-6	N/A
3/31/2024	15	-12	-6	-6	N/A
12/31/2023	15	-15	-5	-5	N/A
9/30/2023	15	-13	-9	-8	N/A
6/30/2023	15	-11	-12	-11	N/A
3/31/2023	15	-11	-14	-13	N/A
12/31/2022	15	-12	-15	-14	N/A
9/30/2022	12	-15	-17	-16	N/A
6/30/2022	9	-17	-19	-18	N/A
3/31/2022	6	-18	-18	-16	N/A
12/31/2021	4	-19	-16	-15	N/A
9/30/2021	4	-17	-13	-12	N/A
6/30/2021	4	-15	-11	-10	N/A
3/31/2021	5	-13	-12	-11	N/A
12/31/2020	6	-11	-13	-12	N/A
9/30/2020	5	-10	-12	-11	N/A
6/30/2020	4	-10	-12	-9	N/A
3/31/2020	3	-9	-11	-8	N/A
12/31/2019	2	-8	-10	-7	N/A
9/30/2019	2	-9	-9	-7	N/A
6/30/2019	2	-10	-9	-7	N/A
3/31/2019	2	-14	-9	-8	N/A
12/31/2018	2	-18	-10	-9	N/A
9/30/2018	2	-17	-9	-8	N/A
6/30/2018	2	-17	-8	-8	N/A
3/31/2018	1	-14	N/A	-9	N/A
12/31/2017	1	-11	N/A	-11	N/A
9/30/2017	1	-12	N/A	-11	N/A
6/30/2017	1	-13	N/A	-11	N/A
3/31/2017	1	-13	N/A	-10	N/A
12/31/2016	1	-13	N/A	-9	N/A
9/30/2016	1	-12	N/A	-11	N/A
6/30/2016	1	-11	N/A	-13	N/A
3/31/2016	1	-12	N/A	-10	N/A
12/31/2015	0	-13	N/A	-8	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-10	N/A	-6	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MX1 önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.4% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: MX1 önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: MX1 önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: MX1 şirketinin gelirinin (yıllık 38.2% ) Australian pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MX1 şirketinin gelirinin (yıllık 38.2% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MX1 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Micro-X Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2027

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Micro-X Limited, Annual General Meeting, Nov 12, 2024

Full year 2024 earnings released

Forecast to breakeven in 2027

Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million.

New minor risk - Shareholder dilution

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Reveals First Look At New Mobile Stroke Diagnosis Device

New minor risk - Profitability

Micro-X Limited, Annual General Meeting, Nov 16, 2023

Full year 2023 earnings released: AU$0.022 loss per share (vs AU$0.037 loss in FY 2022)

New minor risk - Financial data availability

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.019 loss in 1H 2022)

Less than half of directors are independent

Micro-X Limited announced that it has received AUD 7.454223 million in funding from Varex Imaging Corporation

Less than half of directors are independent

Less than half of directors are independent

Micro-X Limited, Annual General Meeting, Nov 14, 2022

Micro-X Limited Announces Resignation of Yasmin King as Director

Micro-X Limited announced that it expects to receive AUD 7.454223 million in funding from Varex Imaging Corporation

Micro-X Limited Launches Next Generation Micro-X Rover, the Rover Plus

Full year 2022 earnings released: AU$0.037 loss per share (vs AU$0.037 loss in FY 2021)

Micro-X Ltd Appoints Ilona Meyer to Its Board as A Non-Executive Director and Member of the Micro-X Audit & Risk Committee, Effective 7Th March 2022

Forecast to breakeven in 2024

Full year 2021 earnings released: AU$0.037 loss per share (vs AU$0.043 loss in FY 2020)

Forecast to breakeven in 2024

Micro-X Ltd Launches New Version of the Rover Mobile DR for Use in Small-Animal Veterinary Hospitals

Micro-X Limited Announces Rover FDA Approval Opens US Healthcare Market

First half 2021 earnings released: AU$0.013 loss per share (vs AU$0.025 loss in 1H 2020)

New 90-day high: AU$0.40

Micro-X Limited announced that it expects to receive AUD 30.5 million in funding

New 90-day high: AU$0.39

Micro-X Limited Signs $1.3 Million Rover Contract for Australian Defence Force

New 90-day high: AU$0.38

Micro-X Limited Announces Rejoining of Jim McDowell as Non-Executive Director from January 1, 2021

Micro-X Limited Amends Nano Distribution Agreement with Carestream Health Inc

Micro-X Ltd Announces Management Changes

New 90-day high: AU$0.26

Micro-X Limited Signs $1.4 Million Contract for Rover Launches Micro-X Second Product

New 90-day high: AU$0.21

Micro-X Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.043 loss per share

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin